Q&A: Can oncolytic viruses make a comeback? Experts dissect clinical failures and outline path forward

17 Nov 2023

ImmunotherapyClinical Study

In the eight years since the FDA first approved an oncolytic virus as a cancer therapy, developers have been striving — and largely failing — to bring next-gen treatments to the market. But a new wave could be upon us. Can oncolytic viruses make a comeback? That was a topic of a recent panel hosted by Endpoints News . Our guests were Paul Peter Tak , a former GSK exec who’s now CEO of viral immunotherapy developer Candel Therapeutics; Howard Kaufman , the president and CEO of Ankyra Therapeutics and a longtime researcher of oncolytic viruses; and Adina Pelusio , the senior vice president of clinical operations at KaliVir Immunotherapeutics, who has more than 20 years of experience leading clinical trials for these therapies.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

GSK Plc

Candel Therapeutics, Inc.

Ankyra Therapeutics, Inc.

[+1]

Indications

Neoplasms

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.